Company intelligence / Profile preview
Verdiva Bio
Guildford, England, United Kingdomverdivabio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Verdiva Bio’s lead asset, VRB‑101—an oral GLP‑1 peptide—has demonstrated compelling efficacy potential in a completed phase 1 study that confirmed the viability of once-weekly dosing. The company is advancing additional programs including oral and subcutaneous amylin agonists. The pipeline is designed to offer best-in-class or first-in-class therapies for obesity and cardiometabolic conditions, leveraging proprietary oral peptide delivery technology. A phase 2 trial of the lead GLP‑1 candidate is planned for this year.[8]
- Therapeutic areas
- Metabolic DisordersEndocrinologyCardiovascular
- Modalities
- Oral peptides (GLP-1 agonists)Amylin agonists (oral and subcutaneous)Dual amylin and calcitonin receptor agonist (DACRA)[1][8]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Licensed three candidates from Sciwind Biosciences in China.[8]Investors include Forbion, General Atlantic, RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital.[4][6]
Beyond the preview
Go deeper on Verdiva Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verdiva Bio.